Edition:
United States

Puma Biotechnology Inc (PBYI.OQ)

PBYI.OQ on NASDAQ Stock Exchange Global Select Market

50.95USD
4:00pm EDT
Change (% chg)

$-0.50 (-0.97%)
Prev Close
$51.45
Open
$51.35
Day's High
$53.60
Day's Low
$50.80
Volume
129,361
Avg. Vol
259,649
52-wk High
$136.90
52-wk Low
$50.50

Chart for

About

Puma Biotechnology, Inc. is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous))... (more)

Overall

Beta: 0.02
Market Cap(Mil.): $1,943.11
Shares Outstanding(Mil.): 37.77
Dividend: --
Yield (%): --

Financials

  PBYI.OQ Industry Sector
P/E (TTM): -- 237.88 32.90
EPS (TTM): -6.53 -- --
ROI: -171.18 -7.38 12.74
ROE: -216.53 -10.11 14.64

BRIEF-Puma Biotechnology Q1 Loss Per Share $0.65

* PUMA BIOTECHNOLOGY REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

May 09 2018

BRIEF-Puma Biotechnology And Pint Pharma Enter Licensing Agreement To Commercialize Nerlynx In Latin America

* PUMA BIOTECHNOLOGY AND PINT PHARMA ENTER INTO EXCLUSIVE LICENSING AGREEMENT TO COMMERCIALIZE NERLYNX® (NERATINIB) IN LATIN AMERICA

Apr 03 2018

BRIEF-Puma Biotechnology ‍Nerlynx Included As Recommended Treatment Option In NCCN Clinical Practice Guidelines

* ‍NERLYNX INCLUDED AS RECOMMENDED TREATMENT OPTION IN NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY CENTRAL NERVOUS SYSTEM CANCERS

Apr 02 2018

BRIEF-Puma Biotechnology Requests EMA To Re-Examine the Negative Opinion Issued By CHMP For MAA For Neratinib

* PUMA BIOTECHNOLOGY SAYS ‍GIVEN WRITTEN NOTICE TO EMA TO REQUEST RE-EXAMINATION OF NEGATIVE OPINION ISSUED BY CHMP IN FEB 2018 FOR MAA FOR NERATINIB Source text for Eikon: (http://bit.ly/2G6kIc2) Further company coverage:

Mar 08 2018

BRIEF-Puma Biotechnology Inc Files For Non Timely 10-K - SEC Filing‍​

* PUMA BIOTECHNOLOGY INC FILES FOR NON TIMELY 10-K - SEC FILING‍​ Source text: (http://bit.ly/2F6s3qK) Further company coverage:

Mar 01 2018

BRIEF-Puma Biotechnology Q4 Loss Per Share $1.71

* PUMA BIOTECHNOLOGY REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

Mar 01 2018

BRIEF-EMA Recommends Against Approval Of Puma Biotechnology's Breast Cancer Drug Neratinib‍​

* EU MEDICINES AGENCY RECOMMENDATIONS FOR FEBRUARY 2018 BREAST CANCER DRUG NERATINIB

Feb 23 2018

BRIEF-Puma Biotechnology And Canbridge Life Sciences Enter Into Exclusive Licensing Agreement To Commercialize Nerlynx In Greater China

* PUMA BIOTECHNOLOGY AND CANBRIDGE LIFE SCIENCES ENTER INTO EXCLUSIVE LICENSING AGREEMENT TO COMMERCIALIZE NERLYNX® (NERATINIB) IN GREATER CHINA Source text for Eikon: Further company coverage:

Feb 01 2018

BRIEF-Puma Biotechnology And Canbridge Life Sciences Enter Into Exclusive Licensing Agreement

* PUMA BIOTECHNOLOGY AND CANBRIDGE LIFE SCIENCES ENTER INTO EXCLUSIVE LICENSING AGREEMENT TO COMMERCIALIZE NERLYNX® (NERATINIB) IN GREATER CHINA

Feb 01 2018

BRIEF-Puma Biotechnology And Medison Pharma Enter Licensing Agreement To Commercialize Nerlynx In Israel

* PUMA BIOTECHNOLOGY AND MEDISON PHARMA ENTER INTO EXCLUSIVE LICENSING AGREEMENT TO COMMERCIALIZE NERLYNX® (NERATINIB) IN ISRAEL

Jan 30 2018

Earnings vs. Estimates